A Phase 3 Evaluation of Sutacimig in Glanzmann Thrombasthenia
a study on Thrombasthenia Anemia Blood Coagulation Disorder Hematologic Disease
Summary
- Eligibility
- for people ages 12-70 (full criteria)
- Location
- at Sacramento, California and other locations
- Dates
- study startedstudy ends around
Description
Summary
Glanzmann thrombasthenia (GT) is a serious inherited bleeding disorder. In GT, platelets, the blood cells that normally stick together at the site of an injury to stop bleeding, are unable to properly do so. As a result, bleeding does not stop as it should. Bleeding in GT often starts without warning, can happen frequently, and can be severe. It most commonly affects the nose, mouth and gums, gastrointestinal tract, and skin, and many women and girls with GT experience heavy menstrual bleeding. Over time, bleeding can lead to iron deficiency and anemia. Some bleeding episodes require emergency care, hospitalization, transfusion, or surgery, and some can be life-threatening.
Sutacimig is an investigational medicine given as an injection under the skin (subcutaneous injection). It is designed to help platelets work at the site of bleeding despite the underlying defect in GT. It is intended to be given regularly to help prevent bleeding (prophylaxis), rather than only to treat bleeding after it starts.
The purpose of this study is to find out whether sutacimig, given as prophylaxis, reduces the number of treated bleeding episodes in people with GT compared with no prophylaxis, and to evaluate its safety and tolerability.
Official Title
SOLARA: A Phase 3 Study of the Efficacy and Safety of Sutacimig in Participants With Glanzmann Thrombasthenia
Keywords
Thrombasthenia, Glanzmann, Glanzmann Thrombasthenia, Bleeding, Glanzmann's thrombasthenia, GT, Inherited Platelet Function Disorder, Rare Bleeding Disorder, ITGA2B, ITGB3, GPIIb/IIIa, Sutacimig, HMB-001, Epistaxis, Iron Deficiency Anemia, Blood Coagulation Disorders, Inherited Blood Coagulation Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, Blood Platelet Disorders, Hemorrhagic Disorders, Genetic Diseases, Inborn, Congenital Hereditary, Neonatal Diseases and Abnormalities, Hemorrhage, Iron-Deficiency Anemia, Inborn Genetic Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Eligibility
You can join if…
Open to people ages 12-70
- Has the ability to provide informed consent to participate in the clinical study before completing any study-related procedures, and has an understanding, ability, and willingness to comply with clinical study procedures and restrictions.
- Adults 18 to 70 years.
- Adolescents 12 to <18 years, dependent on geographical location.
- Has clinical bleeding phenotype consistent with Glanzmann thrombasthenia (GT) and documentation of either diagnostic laboratory criteria (a) or (b) below:
- Abnormal platelet aggregometry AND flow cytometry
- A confirmed genetic mutation in ITGA2B or ITGB3.
- Participants have experienced at least four treated bleeding events related to GT within the 12 months prior to Screening.
You CAN'T join if...
- Prior exposure to sutacimig.
- History of clinically significant hypersensitivity associated with monoclonal antibody therapies.
- Congenital or acquired bleeding disorders other than GT.
- Medical condition (other than GT) that constitutes an increased risk of having uncontrolled bleeding events during the study or other conditions per Investigator discretion.
- History of venous or arterial thromboembolic (TE) event or TE disease except for catheter-associated vein thrombosis.
- Co-existing thrombophilia disorder.
Locations
- University of California Davis (UC Davis) Medical Center
accepting new patients
Sacramento California 95817 United States - University of California San Francisco (UCSF) Medical Center
accepting new patients
San Francisco California 94143 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Hemab ApS
- ID
- NCT07935356
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 76 study participants
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study, which might include an external sponsor. Providing your contact details does not obligate you to participate in the research.
Thank you!
The study team should get back to you in a few business days.